Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP3 | P42574 | 4/20 | 0.48 |
| ▸ | MDM4 | O15151 | 2/20 | 0.47 |
| ▸ | TP53 | P04637 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.43 |
| ▸ | SLC17A5 | Q9NRA2 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3304282 | 1.00 | CASP3 (0.48) | CASP3MDM4TP53KMT2AMDM2 | |
| SCHEMBL5140012 | 1.00 | CASP3 (0.48) | CASP3MDM4TP53KMT2AMDM2 | |
| SCHEMBL2367241 | 0.87 | CASP3 (0.50) | CASP3MDM4TP53KMT2A | |
| SCHEMBL1738651 | 0.87 | CASP3 (0.50) | CASP3MDM4TP53KMT2A | |
| SCHEMBL31575313 | 0.87 | CASP3 (0.50) | CASP3MDM4TP53KMT2A | |
| SCHEMBL2366569 | 0.87 | CASP3 (0.50) | CASP3MDM4TP53KMT2A | |
| SCHEMBL119402 | 0.87 | CASP3 (0.50) | CASP3MDM4TP53KMT2A | |
| SCHEMBL2366563 | 0.87 | CASP3 (0.50) | CASP3MDM4TP53KMT2A | |
| SCHEMBL30252212 | 0.87 | CASP3 (0.50) | CASP3MDM4TP53KMT2A | |
| SCHEMBL29401455 | 0.87 | CASP3 (0.50) | CASP3MDM4TP53KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100099845-A1 | PROTECTED ENANTIOPURE TRIFLUOROTHREONINES AND METHODS OF MAKING AND USING SAME | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 2010-04-22 | — | — | US | claimed |
| US-20100099845-A1 | PROTECTED ENANTIOPURE TRIFLUOROTHREONINES AND METHODS OF MAKING AND USING SAME | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 2010-04-22 | — | — | US | disclosed |
| WO-2008034095-A2 | PROTECTED ENANTIOPURE TRIFLUOROTHREONINES AND METHODS OF MAKING AND USING SAME | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 2008-03-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100099845-A1 | PROTECTED ENANTIOPURE TRIFLUOROTHREONINES AND METHODS OF MAKING AND USING SAME | PTMS, DHPS, DAO | CASP3 2193/4885MDM4 2915/4885TP53 2553/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.